You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
Harvard Business School
McKinsey
Colorcon

Last Updated: February 23, 2024

CLINICAL TRIALS PROFILE FOR DECADRON


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Decadron

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT03995004 ↗ The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery Recruiting The University of Hong Kong Phase 1 2021-10-01 Orthognathic surgery is a procedure performed to correct dentofacial deformities. It involves osteotomy at the facial skeleton. Considerable pain is expected in the early recovery period. Melatonin is a hormone that is produced naturally by the body. Synthetic Melatonin is available over the counter for the management of sleeping disorder and jetlag. Clinically, Melatonin can also be used to reduce pain and analgesic consumption in patients undergoing surgery. Dexamethasone is a type of steroid. It can suppress the inflammatory response. It is an anti-inflammatory, anti-allergic drug. It is commonly used in head and neck and oral surgery for its anti-inflammatory effect to reduce swelling. This study aims evaluate the efficacy of oral melatonin in the pain reduction following orthognathic surgery. This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone. Postoperative pain level and perioperative plasma levels of inflammatory markers and anti-oxidizing enzymes will be recorded and compared among the study groups.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Decadron

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002744 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002744 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 1996-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002798 ↗ Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 3 1996-08-01 Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed Children's Oncology Group Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002816 ↗ Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Decadron

Condition Name

Condition Name for Decadron
Intervention Trials
Multiple Myeloma 92
Recurrent Plasma Cell Myeloma 37
Leukemia 33
Refractory Plasma Cell Myeloma 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Decadron
Intervention Trials
Multiple Myeloma 198
Neoplasms, Plasma Cell 190
Leukemia 89
Precursor Cell Lymphoblastic Leukemia-Lymphoma 80
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Decadron

Trials by Country

Trials by Country for Decadron
Location Trials
Canada 216
Australia 90
New Zealand 29
Puerto Rico 21
China 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Decadron
Location Trials
Texas 145
California 112
New York 99
Massachusetts 97
Minnesota 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Decadron

Clinical Trial Phase

Clinical Trial Phase for Decadron
Clinical Trial Phase Trials
Phase 4 41
Phase 3 75
Phase 2/Phase 3 9
[disabled in preview] 346
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Decadron
Clinical Trial Phase Trials
Completed 209
Recruiting 81
Active, not recruiting 68
[disabled in preview] 125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Decadron

Sponsor Name

Sponsor Name for Decadron
Sponsor Trials
National Cancer Institute (NCI) 186
M.D. Anderson Cancer Center 84
Mayo Clinic 32
[disabled in preview] 70
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Decadron
Sponsor Trials
Other 557
Industry 257
NIH 189
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Johnson and Johnson
Colorcon
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.